Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

The development of guidelines is one of the core activities of the European Society for
Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as …

Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …

Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer
and has a poor outcome. It has been proposed that fallopian tube cancers may be …

Regulatory programs that control the function of stem cells are active in cancer and confer
properties that promote progression and therapy resistance. However, the impact of a stem …

Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous
recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to …